NCT03022318View on ClinicalTrials.gov

Carbidopa-levodopa in Neovascular AMD

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 2, 2017

Primary Completion Date

December 26, 2019

Study Completion Date

May 4, 2020

Conditions
Age-related Macular Degeneration
Interventions
DRUG

carbidopa-levodopa 25-100 mg tablets

See arm/group descriptions

Trial Locations (1)

85712

Robert W Snyder, MD, PhD, PC, Tucson

All Listed Sponsors
lead

Snyder, Robert W., M.D., Ph.D., P.C.

INDIV

NCT03022318 - Carbidopa-levodopa in Neovascular AMD | Biotech Hunter | Biotech Hunter